Price
$0.795
Increased by +3.45%
Dollar Volume (20D)
1.04 M
ADR%
10.3
Earnings Report Date (estimate)
Mar 20, 24
Shares Float
2.51 M
Shares Outstanding
2.96 M
Shares Short
213.08 K
Market Cap.
2.31 M
Beta
1.63
Price / Earnings
0.11
20D Range
0.77 1.56
50D Range
0.77 2.19
200D Range
0.77 5
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 23 -0.27
Increased by +49.06%
-1.84
Increased by +85.33%
Aug 9, 23 -2.15
Increased by +20.66%
-7
Increased by +69.29%
May 11, 23 -5.91
Decreased by -56.35%
-7.5
Increased by +21.2%
Mar 22, 23 -5
Increased by +37.5%
-11.5
Increased by +56.52%
Nov 7, 22 -0.53
Increased by +92.64%
-0.44
Decreased by -20.45%
Aug 11, 22 -2.71
Increased by +66.13%
-3.7
Increased by +26.76%
May 12, 22 -3.78
Increased by +52.75%
-6
Increased by +37%
Mar 30, 22 -8
Increased by 0%
-6
Decreased by -33.33%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 6.66 M
Increased by +121.92%
-799 K
Increased by +96.38%
Decreased by -11.99%
Increased by +98.37%
Jun 30, 23 5.5 M
Increased by +158.84%
-3.81 M
Increased by +70.79%
Decreased by -69.22%
Increased by +88.72%
Mar 31, 23 3.81 M
Increased by +116.52%
-3.61 M
Increased by +69.33%
Decreased by -94.68%
Increased by +85.83%
Dec 31, 22 4 M
Increased by +163.94%
-13.28 M
Increased by +43.15%
Decreased by -332.31%
Increased by +78.46%
Sep 30, 22 3 M
Increased by +133.26%
-22.05 M
Decreased by -31.46%
Decreased by -734.48%
Increased by +43.64%
Jun 30, 22 2.13 M
Increased by +79.41%
-13.04 M
Increased by +26.06%
Decreased by -613.36%
Increased by +58.79%
Mar 31, 22 1.76 M
Increased by +1.42 K%
-11.77 M
Increased by +31.29%
Decreased by -668.31%
Increased by +95.47%
Dec 31, 21 1.51 M
Increased by +102.14%
-23.36 M
Decreased by -32.57%
Decreased by -1.54 K%
Increased by +34.42%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.